ADMA Biologics (NASDAQ:ADMA) Raised to Hold at Zacks Research

ADMA Biologics (NASDAQ:ADMA) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

Other analysts have also issued reports about the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Wall Street Zen lowered ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Cantor Fitzgerald reiterated a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Mizuho cut their price objective on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, Raymond James Financial initiated coverage on ADMA Biologics in a report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 target price on the stock. Three analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $19.67.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $9.21 on Monday. The business has a 50 day simple moving average of $8.62 and a 200 day simple moving average of $12.82. The company has a debt-to-equity ratio of 0.51, a current ratio of 6.95 and a quick ratio of 3.93. The firm has a market capitalization of $2.13 billion, a price-to-earnings ratio of 13.54 and a beta of 0.73. ADMA Biologics has a 12-month low of $7.21 and a 12-month high of $20.46.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.19. The company had revenue of $114.49 million during the quarter, compared to analyst estimates of $139.98 million. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The firm’s quarterly revenue was down .3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.11 EPS. On average, equities research analysts anticipate that ADMA Biologics will post 0.82 EPS for the current year.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Jerrold B. Grossman acquired 12,500 shares of ADMA Biologics stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average price of $8.01 per share, with a total value of $100,125.00. Following the purchase, the director owned 513,884 shares in the company, valued at approximately $4,116,210.84. This trade represents a 2.49% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 3.90% of the company’s stock.

Hedge Funds Weigh In On ADMA Biologics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC boosted its stake in ADMA Biologics by 3,906.1% during the 4th quarter. Janus Henderson Group PLC now owns 3,936,419 shares of the biotechnology company’s stock valued at $71,820,000 after purchasing an additional 3,838,158 shares during the period. Capital Research Global Investors grew its stake in ADMA Biologics by 104.0% during the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock worth $121,067,000 after buying an additional 3,383,559 shares during the last quarter. Caligan Partners LP acquired a new position in shares of ADMA Biologics in the 3rd quarter worth approximately $38,653,000. UBS Group AG lifted its position in ADMA Biologics by 129.9% during the 4th quarter. UBS Group AG now owns 4,569,343 shares of the biotechnology company’s stock worth $83,345,000 after buying an additional 2,581,670 shares in the last quarter. Finally, Sachem Head Capital Management LP increased its holdings in shares of ADMA Biologics by 27.0% in the fourth quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock valued at $207,480,000 after purchasing an additional 2,415,000 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Key Headlines Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Zacks Research upgraded ADMA Biologics from “strong sell” to “hold,” which may provide a small sentiment boost by suggesting the stock is no longer viewed as an outright avoid. Zacks.com
• Neutral Sentiment: ADMA is receiving repeated investor notices from several law firms about the pending securities class action and lead-plaintiff deadline, which mostly reinforces the existing legal uncertainty rather than adding new business fundamentals.
• Negative Sentiment: The largest drag on the stock is the class-action lawsuit and related allegations that ADMA inflated reported growth through channel stuffing, which could raise concerns about revenue quality and management credibility.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.